Thyroid dysfunctions induced by molecular cancer therapies: a synopsis for nuclear medicine thyroidologists

Petra Petranović Ovčariček^{1

2}, Desiree Deandreis^{3

4}, Luca Giovanella^{3

5

6}

Affiliations

¹ EANM Thyroid Committee, Vienna, Austria. p.petranovic@gmail.com.
² Department of Oncology and Nuclear Medicine, University Hospital Center "Sestre milosrdnice", Vinogradska 29, 10 000, Zagreb, Croatia. p.petranovic@gmail.com.
³ EANM Thyroid Committee, Vienna, Austria.
⁴ Department of Medical Sciences, Nuclear Medicine Division, AOU Città della Salute e della Scienza, University of Turin, Turin, Italy.
⁵ Clinic for Nuclear Medicine and Competence Centre for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
⁶ Clinic for Nuclear Medicine, University Hospital and University of Zurich, Zurich, Switzerland.

Editorial

Petra Petranović Ovčariček et al. Eur J Nucl Med Mol Imaging. 2021 Oct.

. 2021 Oct;48(11):3355-3360.

doi: 10.1007/s00259-021-05394-0.

Petra Petranović Ovčariček^{1

2}, Desiree Deandreis^{3

4}, Luca Giovanella^{3

5

6}

¹ EANM Thyroid Committee, Vienna, Austria. p.petranovic@gmail.com.
² Department of Oncology and Nuclear Medicine, University Hospital Center "Sestre milosrdnice", Vinogradska 29, 10 000, Zagreb, Croatia. p.petranovic@gmail.com.
³ EANM Thyroid Committee, Vienna, Austria.
⁴ Department of Medical Sciences, Nuclear Medicine Division, AOU Città della Salute e della Scienza, University of Turin, Turin, Italy.
⁵ Clinic for Nuclear Medicine and Competence Centre for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
⁶ Clinic for Nuclear Medicine, University Hospital and University of Zurich, Zurich, Switzerland.

No abstract available

References

1. Bhattacharya S, Goyal A, Kaur P, Singh R, Kalra S. anticancer drug-induced thyroid dysfunction. Eur Endocrinol. 2020 [cited 2020 Jun 29];16(1):32. Available from: https://www.touchendocrinology.com/anticancer-drug-induced-thyroid-dysfu... .
1. Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Muramaki M, Takenaka A, et al. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol. 2010 [cited 2021 Apr 12];28(5):515–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19914105 .
1. Eroukhmanoff J, Castinetti F, Penel N, Salas S. Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma. BMC Cancer. 2016 [cited 2020 Jul 7];16(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997685/ .
1. Abdel-Rahman O, Fouad M. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. Expert Rev Anticancer Ther. 2014 Sep 13 [cited 2020 May 5];14(9):1063–73. Available from: http://www.tandfonline.com/doi/full/10.1586/14737140.2014.929501 .
1. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017 Apr 20 [cited 2020 May 4];13(4):195–207. Available from: http://www.nature.com/articles/nrendo.2016.205 .